BK0092 Medical Devices
- 959.132
- +1.077+0.11%
Science and Technology Innovation Board Evening News|Aisen Co., Ltd. plans to invest in an integrated circuit materials project, shareholders of Kemei Diagnostics plan to reduce their holdings
① National Data Administration: Exploring collaboration between the central government and the region to promote digital transformation and institutional innovation; ② Guangzhou initiates legislative work on the “Low-Altitude Economic Development Regulations”; ③ Lihewei: Shareholder Chen Jincheng made a bulk transaction to reduce the company's shares by 350,000 shares; ④ China Innovation Co., Ltd. plans to distribute a cash dividend of 2.4 yuan for every 10 shares in 2023.
Antu Biotech: Mining and landing in Anhui will have a positive impact, and the proportion of reagent products will increase | Direct performance
① Mr. Feng Chao, financial director of Antu Biotech, said bluntly during the performance meeting that the share of reagent products will increase in the future; ② Chairman Miao Yongjun predicted the growth rate of the molecular, microbiological and other sectors. Among them, there is little new market space in the biochemical sector; ③ Secretary Fang Ruikuan believes that a national collection meeting is likely, and that the mining and landing in Anhui will have a positive impact on the company.
An Xu Biotech: Mainly drug testing and infectious disease testing products after COVID-19 | Direct performance report
① “After the demand for COVID-19 testing declined, the company's products are currently mainly drug testing products and infectious disease testing products.” ② In the future, An Xu Biotech will also need to address at least two aspects of single addiction, including excessive reliance on overseas income and a single dependency on product income.
Passed! Pharmacovigilance waited for an 8-year buffer period, and the company quickly responded
The new version of the US Biosafety Act (H.R. 8333) (hereinafter referred to as the “Act”) has ushered in the latest developments.
Mountain Wai Shan: Increase Market Development Efforts in Emerging Countries and Participate in Market Competition in Compliance with the Law | Direct Performance Meeting
① “Although tendering and procurement have been delayed, procurement demand itself has not been affected. As this year's rectification becomes normalized, it is expected that the postponed procurement projects will gradually resume.” ② “The company's products have been sold to 75 countries and regions around the world, and the most impressive growth performance is still developing countries.”
Looking for the 3 billion market? Shengxiang Biological Water Test Rapid Drug Sensitivity Test Track
① “We still do it in the form of strategic investment rather than financial investment. Newly established companies are not included in the scope of the company's statements.” ② If Hunan Shengwei Sumin's subsequent business becomes more mature, it is not ruled out that Shengxiang Biotech will take more actions other than strategic investment.
Deciphering the new investment trends of social security funds in the first quarter: the top ten tradable shareholders added to 220 individual stocks, and Inke Healthcare received the largest number of shareholders
① The first quarterly report of A-share listed companies was revealed, and a total of 667 shares of the top ten tradable shareholders were revealed; ② Among them, the Social Security Fund entered the list of the top ten tradable shareholders of 220 individual shares, with Inke Healthcare receiving the most additional holdings and the list of individual stocks with more than 2 additional holdings (attached table); ③ Zhejiang Electric Power received the most new shares in the first quarter, and Wanhua Chemical received the highest market value of new holdings.
Dental product revenue declines year by year, and Aojing Medical's foreign acquisitions extend to implants
① In recent years, dental products are the only products among the three main products whose revenue has declined year by year, and gross margin has also declined year by year. ② The acquisition of a brand imported from Germany is expected to increase the technology and market share of Aojing Medical.
The lawsuit extends to the rival base of the industry, and the dispute between Egg Biotech and the shareholders of the subsidiary intensifies
① Recently, the small and medium shareholders of Jingchuan Diagnostics were sued by the small and medium shareholders of Jingchuan Diagnostics, and this is only one part of the fight between the two sides; ② Jingchuan Diagnostics made an exclusive response to the Financial Federation reporter saying that several lawsuits have only been filed in August of last year, and that management and employees expect the dispute to be resolved as soon as possible; ③ the industry believes that the intention to continue to acquire Gidao Biotech is not strong, or that it has caused a “soft confrontation” with Jingchuan Diagnosis.
Can Kangtuo Medical's core business grow year by year to solve the dilemma of increasing revenue or not increasing profit? |Go directly to the results meeting
① “PEEK neurosurgical products have obvious performance advantages over traditional titanium products. In recent years, with continuous market education and marketing promotion, the penetration rate of PEEK material products has increased year by year.” ② The successive implementation of collection has led to a decline in terminal prices, forcing the price of Kangtuo medical products to drop year-on-year in regions where collection has not yet been carried out.
50 billion! Another college science and technology innovation parent fund established Tianjin University to run out of several unicorns
① Tiankai Jiu'an Haihe Begonia Science and Technology Innovation Parent Fund was officially registered and established, with a scale of 5 billion yuan. In recent years, Tianjin University has continued to make efforts to transform scientific and technological achievements, with an annual funding of 4 billion yuan for scientific research. ② Deep Blue, Yisiwei, and Jingfeng Medical are all proposed IPOs from Tianjin University.
Xiangsheng Medical's share of overseas revenue reached a record high, driving positive revenue growth in 2023 with a dividend rate of over 60%
① Overseas markets were reduced by the impact of the epidemic in 2023 and resumed growth, which in turn led to an increase in annual performance. ② “The company's overseas market business layout is scattered, not concentrated in a specific region, and there are no detailed divisions in terms of revenue.”
Northbound Capital Purchase Report: Mindray Healthcare Receives Net Sales of 416 Million Yuan
Northbound Capital had a sharp net sale of 2,793 billion yuan today.
Splice up the IVD business layout! Hot Scene Biotech “went around the corner” to buy back the former upstream subsidiary
① After acquiring Kaijing Gene, Hejing Biotech rearranged the complete industrial chain from upstream key bioactive ingredients for in vitro diagnosis to R&D, production, and sales of reagents and instruments; ② “In the future, we will also create more business for Kaijing Gene, and revenue and profits are expected to continue to grow.”
Heavy warehouse bought back Meituan Kuaishou! Zhong Geng Qiu Dongrong's quarterly report revealed that there were many moves to adjust positions
Early this morning, Qiu Dongrong's products revealed a quarterly report.
Non-COVID-19 business boosts Innotek's performance in 2023 to maintain growth and significantly increase dividends
① In 2023, the non-COVID-19 business achieved revenue of 420 million yuan, an increase of 208.23% over the previous year, accounting for 87.82% of the overall revenue. ② “The company has registered products in Southeast Asia, but products in Europe and the US have not been released yet.”
Overseas market contribution rate continues to rise, Huitai Healthcare's revenue increased 36%, breaking 1.6 billion
① Benefiting from the active expansion of domestic and foreign markets, Huitai Healthcare's revenue and net profit in 2023 will continue to grow at a high level. ② In 2023, the plan is to pay 20 yuan in cash for every 10 shares and add 4.5 shares. The total proposed cash dividend is 133 million yuan, accounting for 24.93% of net profit to mother.
Subsidiary signs investment agreement with Dark Side of the Moon for 25 billion Kimi Concept Shares issued a change announcement|Highlights of post-market announcements
Zhongtai Chemical: The Securities Regulatory Commission decided to file a case against the controlling shareholder Zhongtai Group due to suspected illegal information disclosure
Sales of blood purification equipment and related consumables “double increased” Shanwai Mountain's net profit in 2023 increased 227.64% year-on-year
① In the fourth quarter of 2023, Shanwai Mountain achieved revenue and net profit of 114 million yuan and net profit to mother of 112 million yuan, respectively, while net profit after deducting non-net profit was -0.04 billion yuan. ② The company said that as self-produced blood purification consumables products are launched one after another, collection will rapidly increase the number of hospitals covered by the company's consumables, which will greatly promote product sales.
Science and Technology Innovation Board Evening News | Fangyuan Co., Ltd., Nanxin Technology, etc. plan to buy back Sanyou Medical and Jiete Biotech Real Controllers to increase their holdings
① The Securities Regulatory Commission held the first offline press conference in the Year of the Dragon. Currently, there are no plans for a 10-year IPO backcheck, which will greatly increase the proportion of on-site inspections of companies to be listed; ② the Science and Technology Innovation 50 Index will be adjusted regularly in the first quarter to transfer to 3 individual stocks of Jinghe Integrated, Artes, and Aviation Materials; ③ Jingjin Electric: Obtaining the target for a three-in-one electric drive assembly project in the European market from a leading global vehicle customer.